Find Grapiprant manufacturers, exporters & distributors on PharmaCompass

Grapiprant

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

4 API Suppliers, 3 NDC API, 2 VMF, 4 Listed Suppliers, $ API Reference Price

4 API Suppliers
3 NDC API
2 VMF
4 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

FINISHED DOSAGE FORMULATIONS

6 FDF Dossiers, 3 Canada, 3 Listed Dossiers

6 FDF Dossiers
3 Canada
3 Listed Dossiers

DIGITAL CONTENT

2 NEWS #PharmaBuzz

media
2 NEWS #PharmaBuzz

MARKET PLACE

2 APIs

marketPlace
2 APIs

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 415903-37-6, Cj-023423, Aat-007, Cj 023423, Rq-7, Rq-00000007

Molecular Formula

C₂₆H₂₉N₅O₃S

Molecular Weight

491.6 g/mol

InChI Key

HZVLFTCYCLXTGV-UHFFFAOYSA-N

FDA UNII

J9F5ZPH7NB

Grapiprant is an orally bioavailable antagonist of the prostaglandin E receptor subtype 4 (EP4), with potential analgesic, immunomodulating and antineoplastic activities. Upon administration of grapiprant, this agent selectively binds to and inhibits the binding of prostaglandin E2 (PGE2) and prevents the activation of the EP4 receptor. This inhibits PGE2-EP4 receptor-mediated signaling and prevents proliferation in tumor cells in which the PGE2-EP4 signaling pathway is over-activated. In addition, EP4 receptor inhibition modulates the immune system by preventing both interleukin-23 (IL-23) production and the IL-23-mediated expansion of Th17 cells. As EP4 is expressed by peripheral sensory neurons, blockade of EP4-mediated signaling may induce an analgesic effect. EP4, a prostanoid receptor subtype, is a G protein-coupled receptor that is expressed in certain types of cancers; it promotes tumor cell proliferation and invasion.

1 2D Structure

Grapiprant

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

1-[2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea

2.1.2 InChI

InChI=1S/C26H29N5O3S/c1-5-24-29-25-19(4)28-18(3)16-23(25)31(24)21-10-8-20(9-11-21)14-15-27-26(32)30-35(33,34)22-12-6-17(2)7-13-22/h6-13,16H,5,14-15H2,1-4H3,(H2,27,30,32)

2.1.3 InChI Key

HZVLFTCYCLXTGV-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CCC1=NC2=C(N1C3=CC=C(C=C3)CCNC(=O)NS(=O)(=O)C4=CC=C(C=C4)C)C=C(N=C2C)C

2.2 Other Identifiers

2.2.1 UNII

J9F5ZPH7NB

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 1-(2-(4-(2-ethyl-4,6-dimethylimidazo(4,5-c)pyridin-1-yl)phenyl)ethyl)-3-(4-methylphenyl)sulfonylurea

2. Aat-007

3. Cj 023,423

4. Cj 023423

5. Cj-023

6. Cj-023,423

7. Cj-023423

8. Mr-10a7

9. Mr10a7

10. N-(((2-(4-(2-ethyl-4,6-dimethyl-1h-imidazo(4,5-c)pyridin-1-yl) Phenyl)ethyl)amino)carbonyl)-4-methylbenzenesulfonamide

11. Rq-00000007

12. Rq-7

2.3.2 Depositor-Supplied Synonyms

1. 415903-37-6

2. Cj-023423

3. Aat-007

4. Cj 023423

5. Rq-7

6. Rq-00000007

7. Mr-10a7

8. Cj-023,423

9. N-((4-(2-ethyl-4,6-dimethyl-1h-imidazo[4,5-c]pyridin-1-yl)phenethyl)carbamoyl)-4-methylbenzenesulfonamide

10. Cj-023

11. Mr10a7

12. J9f5zph7nb

13. Grapiprant (cj-023423)

14. 706802-34-8

15. Cj-023423;rq-00000007;aat-007

16. 1-[2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea

17. Benzenesulfonamide, N-(((2-(4-(2-ethyl-4,6-dimethyl-1h-imidazo(4,5-c)pyridin-1-yl)phenyl)ethyl)amino)carbonyl)-4-methyl-

18. Grapiprant [usan:inn]

19. Unii-j9f5zph7nb

20. 1-(2-(4-(2-ethyl-4,6-dimethylimidazo(4,5-c)pyridin-1-yl)phenyl)ethyl)-3-(4-methylphenyl)sulfonylurea

21. N-(((2-(4-(2-ethyl-4,6-dimethyl-1h-imidazo(4,5-c)pyridin-1-yl)phenyl)ethyl)amino)carbonyl)-4-methylbenzenesulfonamide

22. N-[([2-[4-(2-ethyl-4,6-dimethyl-1h-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]amino)carbonyl]-4-methylbenzenesulfonamide

23. Grapiprant [mi]

24. Grapiprant [inn]

25. Grapiprant (usan/inn)

26. Grapiprant [usan]

27. Grapiprant [who-dd]

28. Schembl120428

29. Gtpl5858

30. Grapiprant [green Book]

31. Chembl3039498

32. Dtxsid60194419

33. Bcp20570

34. Ex-a2544

35. Bdbm50107283

36. S6694

37. Zinc38228051

38. Akos030526811

39. Aat-007cj-023423

40. Cs-5392

41. Db12836

42. Sb18902

43. Ac-36123

44. As-77380

45. Hy-16781

46. A15964

47. D10638

48. D83673

49. A900379

50. Q27077852

51. B0084-470919

52. Cj-023423; Rq-00000007; Aat-007

53. Grapiprant; Rq-00000007; Aat-007; Cj-023423

54. 2-ethyl-4,6-dimethyl-1-(4-(2-(((((4-methylphenyl)sulfonyl)amino)carbonyl)amino)ethyl)phenyl)-1h-imidazo(4,5-c)pyridine

55. Benzenesulfonamide,n-[[[2-[4-(2-ethyl-4,6-dimethyl-1h-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]amino]carbonyl]-4-methyl-

56. N-(((2-(4-(2-ethyl-4,6-dimethyl-1h-imidazo(4,5-c)pyridin-1-yl)phenyl)ethyl)amino)carbonyl)-4-methyl-benzenesulfonamide

2.4 Create Date

2006-10-26

3 Chemical and Physical Properties

Molecular Formula	C₂₆H₂₉N₅O₃S
Molecular Weight	491.6 g/mol
XLogP3	4.6
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	7
Exact Mass	491.19911098 g/mol
Monoisotopic Mass	491.19911098 g/mol
Topological Polar Surface Area	114 Å²
Heavy Atom Count	35
Formal Charge	0
Complexity	802
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

The effects of grapiprant have been investigated in the area of analgesia and anti-inflammation due to the effects that have been reported about this molecule. This molecule has been approved and widely accepted to be used in veterinary for pain reduction in arthritis. In humans, it has been researched to be used in the control of pain and inflammation associated with osteoarthritis. The effect of grapiprant can be explained through the function of prostaglandin E2 (PGE2) which is a key mediator of swelling redness and pain which are classic signs of inflammation. The effect of PGE2 results from its action through four receptor EP1, EP2, EP3 and EP4 from which the EP4 is the primary mediator of PGE2-driven inflammation.

For the treatment of pain associated with mild to moderate osteoarthritis in dogs.

5 Pharmacology and Biochemistry

5.1 Pharmacology

Preclinical studies have shown that grapiprant is very effective to reduce acute and chronic pain and inflammation. The effect of grapiprant seems to be dose-dependent and it is comparable to the effect of rofecoxib and piroxicam. The effects of grapiprant have been reported to be effective in the relief from arthritic pain in canine patients.

5.2 ATC Code

QM01AX92

5.3 Absorption, Distribution and Excretion

Absorption

Studies in animals (horse) have shown the presence of a concentration >0.005 ng/ml in serum 72 hours after initial administration of a dose of 2 mg/kg. It is rapidly absorbed and the reported Cmax in this reports was 31.9 ng/ml in a Tmax of 1.5 hours and AUC of 2000 ng.hr/ml. In the case of bioavailability, grapiprant presents a mean bioavailability of 39%. The bioavailability, time for peak concentration and maximal concentration has been reported to be significantly reduced after food.

Route of Elimination

Following an oral dose, the majority of the dose an within the first 72 hours. Studies in animals (horse) have shown the presence of a concentration >0.005 ng/ml in urine 96 hours after initial administration of a dose of 2 mg/kg. From the excreted dose, 55%, 15% and 19% of the administered dose is excreted in bile, urine, and feces respectively.

Volume of Distribution

The reported volume of distribution in animal studies (cats) was reported to be 918 ml/kg.

Clearance

The reported clearance rate in animal studies (cats) was reported to be 173.2 ml/hr.kg.

5.4 Metabolism/Metabolites

_In vitro_ studies with dog microsomes have reported the identification of four metabolites, an N-deamination metabolite which is the major metabolite in urine and feces, two hydroxylated metabolites and one N-oxidation metabolite.

5.5 Biological Half-Life

The reported elimination half-life in animal studies (horse) is of 5.86 hours.

5.6 Mechanism of Action

Grapiprant is an EP4 prostaglandin receptor antagonist and thus the activity of this drug is thought to be completely related to the selective blockade of this receptor. It binds to human and other mammals EP4 prostaglandin receptor with high affinity without interfering with other prostaglandin pathways which are important for a variety of physiological functions. The binding of grapiprant blocks PGE2 binding and hence its biological effect related to the signaling pain and inflammation cascade. Grapiprant has been accepted very greatly in veterinary as its mechanism of action is a targeted approach to pain management by not having any interaction with the production of prostanoids and thus, by not interacting with other prostaglandin receptor pathways.

API SUPPLIERS

01

Rochem International Inc

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Suppliers Night Expo

Attending

Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

Contact Supplier

U.S.A

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

02

Supriya Lifescience

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Antibody Engineering

Not Confirmed

Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Contact Supplier

India

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

03

Alivira Animal Health

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Antibody Engineering

Not Confirmed

04

Zenfold Sustainable Technologies

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Antibody Engineering

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

01

Sterling Pharma Solutions Limited

United Kingdom

AES 2024

Not Confirmed

02

Jiangsu Tianhe Pharmaceutical Co., ...

China

AES 2024

Not Confirmed

03

Zhejiang Apeloa Jiayuan Pharmaceuti...

China

AES 2024

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

VMF

01

Elanco Us Inc

U.S.A

AES 2024

Not Confirmed

02

Zydus Lifesciences Ltd

India

AES 2024

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

01

Rochem International Inc

U.S.A

Suppliers Night Expo

Attending

Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

Contact Supplier

U.S.A

Virtual Booth

Digital Content

Grapiprant

About the Company : Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quali...

Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quality ingredients manufactured in China. Headquartered in the Hauppauge, New York, Rochem has 16 offices spread across the globe to cater to the needs of its customers. Rochem’s operations are fully cGMP compliant and has been audited by the USFDA as well as several multinational organizations. It also trains and audits its partners to ensure all of their technologies and systems are FDA-compliant.

02

Supriya Lifescience

India

AES 2024

Not Confirmed

Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Contact Supplier

India

Virtual Booth

Digital Content

Grapiprant

About the Company : Supriya Lifescience Ltd. specializes in API manufacturing, focusing on therapeutic segments like antihistamines, anti-allergic drugs, vitamins, anaesthetics and anti-asthmatics. Su...

Supriya Lifescience Ltd. specializes in API manufacturing, focusing on therapeutic segments like antihistamines, anti-allergic drugs, vitamins, anaesthetics and anti-asthmatics. Supriya follows industry standards and constantly improves to deliver quality products. Its facility is 47,000 square meters with dedicated areas for warehouse, QA, QC, R&D, production and finished products. The current capacity is 550 KL, with plans to expand to over 1000 KL by 2024. Supriya has 14 active USDMFs, 8 active CEPs, strong R&D and compliant facilities worldwide. Supriya works with innovators, generic companies, and as a CMO.

03

Alivira Animal Health

India

AES 2024

Not Confirmed

04

Zenfold Sustainable Technologies

India

AES 2024

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

01 Nacuity Pharmaceuticals

U.S.A

Antibody Engineering

Not Confirmed

02 Applied Therapeutics

U.S.A

Antibody Engineering

Not Confirmed

03 Applied Therapeutics

U.S.A

Antibody Engineering

Not Confirmed

04 Applied Therapeutics

U.S.A

Antibody Engineering

Not Confirmed

05 Applied Therapeutics

U.S.A

Antibody Engineering

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

01

Supriya Lifescience

India

Antibody Engineering

Not Confirmed

Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Contact Supplier

India

Virtual Booth

Digital Content

Regulatory Info :

Registration Country : India

Grapiprant

Brand Name :

Dosage Form : Flavoured Tablet

Dosage Strength : 20MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

02

Supriya Lifescience

India

Antibody Engineering

Not Confirmed

Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Contact Supplier

India

Virtual Booth

Digital Content

Regulatory Info :

Registration Country : India

Grapiprant

Brand Name :

Dosage Form : Flavoured Tablet

Dosage Strength : 60MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

03

Supriya Lifescience

India

Antibody Engineering

Not Confirmed

Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Contact Supplier

India

Virtual Booth

Digital Content

Regulatory Info :

Registration Country : India

Grapiprant

Brand Name :

Dosage Form : Flavoured Tablet

Dosage Strength : 100MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

04

NOVARTIS ANIMAL HEALTH CANADA INC

Canada

Antibody Engineering

Not Confirmed

05

NOVARTIS ANIMAL HEALTH CANADA INC

Canada

Antibody Engineering

Not Confirmed

06

NOVARTIS ANIMAL HEALTH CANADA INC

Canada

Antibody Engineering

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

01

Supriya Lifescience

India

Antibody Engineering

Not Confirmed

Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Contact Supplier

India

Virtual Booth

Digital Content

Regulatory Info :

Registration Country : India

Grapiprant

Brand Name :

Dosage Form : Flavoured Tablet

Dosage Strength : 20MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

02

Supriya Lifescience

India

Antibody Engineering

Not Confirmed

Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Contact Supplier

India

Virtual Booth

Digital Content

Regulatory Info :

Registration Country : India

Grapiprant

Brand Name :

Dosage Form : Flavoured Tablet

Dosage Strength : 60MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

03

Supriya Lifescience

India

Antibody Engineering

Not Confirmed

Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Contact Supplier

India

Virtual Booth

Digital Content

Regulatory Info :

Registration Country : India

Grapiprant

Brand Name :

Dosage Form : Flavoured Tablet

Dosage Strength : 100MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

Market Place

Do you need sourcing support? Ask us

APIs

Grapiprant (2.2 kg) API needed in India [ENA16083]

A company that focuses on research, development and manufacturing of OSDs, oral liquids, parenteral & topical solutions for veterinary use is looking for suppliers of Grapiprant (2.2 kg) API for both development and commercial purposes. The suppliers must support this enquiry with CoA.

13 Jan 2023

Grapiprant API needed in India [ENA06159]

An integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health (API and formulation) is looking for suppliers of Grapiprant API. The required quantity will be 1-2 kg for research purposes.

26 Dec 2019

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Market Place

Home

Post Enquiry

Market Place

Find Grapiprant manufacturers, exporters & distributors on PharmaCompass

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

4 API Suppliers

3 NDC API

2 VMF

4 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

5 Drugs in Development

FINISHED DOSAGE FORMULATIONS

6 FDF Dossiers

3 Canada

3 Listed Dossiers

DIGITAL CONTENT

2 NEWS #PharmaBuzz

MARKET PLACE

2 APIs

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 3,790

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

01

02

03

04

01

02

03

01

01

02

02

01

02

03

04

01

02

03

04

05

01

02

03

04

05

06

01

01

02

02

03

03

What are you looking for?